Form 4: Altimmune Chief Scientific Officer Reports Stock Transactions

Altimmune's Chief Scientific Officer, M. Scot Roberts, reported multiple transactions involving the company's common stock and restricted stock units.

Summary

• M. Scot Roberts, Chief Scientific Officer of Altimmune, Inc., filed a Form 4 detailing several transactions.
• These transactions include the vesting of restricted stock units (RSUs), the sale of shares to cover taxes related to RSU vesting, and the purchase of shares through the company's Employee Stock Purchase Plan (ESPP).
• On January 30, 2025, 9,275 RSUs vested, and 2,709 shares were sold at $7 to cover taxes.
• On January 31, 2025, 3,184 shares were purchased at $5.18 through the ESPP.
• On February 1, 2025, 6,166 RSUs vested, and 1,801 shares were sold at $6.64 to cover taxes.
• On February 2, 2025, 7,775 RSUs vested, and 2,316 shares were sold at $6.64 to cover taxes.
• Following these transactions, Roberts directly owns 73,220 shares of Altimmune common stock.

Sentiment

Score: 6

Explanation: The document reflects routine transactions, with no significant positive or negative implications. The sentiment is neutral to slightly positive due to the executive's continued investment in the company.

Positives

• The vesting of RSUs indicates continued service and potential alignment with the company's long-term goals.
• The purchase of shares through the ESPP demonstrates the officer's investment in the company's future.

Negatives

• The sale of shares to cover taxes, while standard, slightly reduces the officer's direct shareholding.

Risks

• The transactions are routine and do not indicate any specific risks.
• The stock price fluctuations could impact the value of the holdings.

Industry Context

These transactions are typical for executives who receive stock-based compensation and participate in employee stock purchase plans. It is common for executives to sell shares to cover tax obligations when RSUs vest.

Comparison to Industry Standards

• The vesting schedule of the RSUs, with annual installments over four years, is a common practice in the biotechnology industry.
• The ESPP purchase at 85% of the closing price is also a standard benefit offered by many companies.
• Similar transactions are regularly reported by executives at comparable companies such as Moderna, BioNTech, and Regeneron.

Stakeholder Impact

• The transactions have a minor impact on shareholders, as they reflect routine executive compensation and do not indicate any significant change in the company's outlook.
• The transactions have no direct impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

Altimmune, Stock Transactions, Form 4, Restricted Stock Units, Employee Stock Purchase Plan, Insider Trading, M. Scot Roberts, Vesting, Share Sales, Share Purchases